Published in J Clin Med Res on August 23, 2015
Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells). PLoS One (2017) 0.75
CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency. Cancer Sci (2017) 0.75
PIG3 promotes NSCLC cell mitotic progression and is associated with poor prognosis of NSCLC patients. J Exp Clin Cancer Res (2017) 0.75
A Vector-Based Short Hairpin RNA Targeting Aurora B Suppresses Human Prostatic Carcinoma Growth. Technol Cancer Res Treat (2016) 0.75
Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet (1998) 8.91
A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J (1998) 7.39
VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med (2004) 6.40
The cellular geography of aurora kinases. Nat Rev Mol Cell Biol (2003) 6.40
Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J (2002) 4.54
Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol Cell (2003) 4.51
Aurora-A - a guardian of poles. Nat Rev Cancer (2005) 4.11
Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res (2008) 3.92
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia (2002) 3.90
Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer (2010) 3.74
AIM-1: a mammalian midbody-associated protein required for cytokinesis. EMBO J (1998) 3.73
Aurora B phosphorylates spatially distinct targets to differentially regulate the kinetochore-microtubule interface. Mol Cell (2010) 3.44
Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet (2003) 3.38
Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin Cancer Res (2012) 3.35
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer (2010) 2.99
Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res (2006) 2.88
A novel mechanism for activation of the protein kinase Aurora A. Curr Biol (2003) 2.68
Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res (1998) 2.63
Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cell (2002) 2.56
Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends Cell Biol (2005) 2.41
Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem (2005) 2.38
Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res (2011) 2.35
Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem (2004) 2.11
Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents (2005) 2.10
Drosophila Aurora-A is required for centrosome maturation and actin-dependent asymmetric protein localization during mitosis. Curr Biol (2002) 2.09
Chfr is required for tumor suppression and Aurora A regulation. Nat Genet (2005) 1.97
Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res (2002) 1.93
Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res (2004) 1.83
MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol (2007) 1.79
Retracted BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem (2004) 1.77
Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer (2001) 1.77
PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther (2007) 1.67
Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal (2010) 1.64
Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res (2012) 1.63
Cell cycle-dependent expression and centrosome localization of a third human aurora/Ipl1-related protein kinase, AIK3. J Biol Chem (1999) 1.59
Centrosome amplification and overexpression of aurora A are early events in rat mammary carcinogenesis. Cancer Res (2002) 1.59
Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res (2012) 1.56
Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs (2012) 1.44
Identification of V23RalA-Ser194 as a critical mediator for Aurora-A-induced cellular motility and transformation by small pool expression screening. J Biol Chem (2005) 1.40
Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem (2009) 1.39
Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab (2004) 1.36
Aurora-C kinase deficiency causes cytokinesis failure in meiosis I and production of large polyploid oocytes in mice. Mol Biol Cell (2010) 1.35
Clinical experience with aurora kinase inhibitors: a review. Oncologist (2009) 1.31
High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers. Cancer Biol Ther (2007) 1.30
GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther (2009) 1.27
Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol (2009) 1.26
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J Cell Mol Med (2011) 1.22
Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence. Ann Intern Med (2006) 1.19
Genetic disruption of aurora B uncovers an essential role for aurora C during early mammalian development. Development (2011) 1.15
Mitotic drivers--inhibitors of the Aurora B Kinase. Cancer Metastasis Rev (2009) 1.14
Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin Cancer Res (2011) 1.14
Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC. BMC Cancer (2010) 1.13
Aurora kinase inhibition downregulates NF-kappaB and sensitises tumour cells to chemotherapeutic agents. Biochem Biophys Res Commun (2006) 1.11
Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck. Oncotarget (2011) 1.10
Inhibitors of cyclin dependent kinases: useful targets for cancer treatment. Curr Cancer Drug Targets (2008) 1.09
Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res (2010) 1.08
Aurora kinase inhibitors. Crit Rev Oncol Hematol (2009) 1.08
Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther (2010) 1.07
Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells. Leuk Lymphoma (2008) 1.07
Aurora-A kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells. Cancer Res (2004) 1.07
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU Int (2012) 1.07
The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing. Eur J Med Chem (2012) 1.05
Evolutionary relationships of Aurora kinases: implications for model organism studies and the development of anti-cancer drugs. BMC Evol Biol (2004) 1.04
Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Arch (2007) 1.03
The mammalian centrosome and its functional significance. Histochem Cell Biol (2008) 1.01
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res (2009) 1.01
Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1. Biochem J (2009) 0.98
Cloning of STK13, a third human protein kinase related to Drosophila aurora and budding yeast Ipl1 that maps on chromosome 19q13.3-ter. Genomics (1998) 0.98
Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia (2009) 0.98
The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther (2009) 0.97
Molecular distinctions between Aurora A and B: a single residue change transforms Aurora A into correctly localized and functional Aurora B. Mol Biol Cell (2009) 0.97
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood (2010) 0.96
SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol (2009) 0.93
Expression of Aurora B and alternative variant forms in hepatocellular carcinoma and adjacent tissue. Cancer Sci (2009) 0.92
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol (2010) 0.92
PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol Cancer Ther (2010) 0.91
Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer. Curr Oncol Rep (2008) 0.90
The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. J Hepatol (2008) 0.90
Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells. Cancer Cell Int (2013) 0.87
Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol (2010) 0.86
Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. Eur J Cancer (2011) 0.86
Expression of Aurora-B kinase and phosphorylated histone H3 in hepatocellular carcinoma. Anticancer Res (2006) 0.86
Overexpression of Aurora-A promotes laryngeal cancer progression by enhancing invasive ability and chromosomal instability. Eur Arch Otorhinolaryngol (2011) 0.85
Oncogenic role of nuclear accumulated Aurora-A. Mol Carcinog (2009) 0.83
Integrating bioinformatics and clinicopathological research of gastrointestinal stromal tumors: identification of aurora kinase A as a poor risk marker. Ann Surg Oncol (2012) 0.82
Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model. Clin Cancer Res (2012) 0.81
Extramammary Paget's disease of the vulva. BMJ Case Rep (2013) 0.81
Sacrococcygeal chordoma, a rare cause of coccygodynia. Am J Case Rep (2013) 0.81
Colon Adenocarcinoma Associated with Synchronous Extramural Gastrointestinal Stromal Tumor (GIST) of the Ileum. Am J Case Rep (2015) 0.78
Early solitary small bowel metastasis from stage I cutaneous melanoma. Am J Case Rep (2013) 0.77
Intramuscular myxoma of the soleus muscle: A rare tumor in an unusual location. Am J Case Rep (2014) 0.77
Solitary metachronous splenic metastasis from cutaneous melanoma. BMJ Case Rep (2012) 0.75